News View All News arrow-button

May 10, 2019

CEO Gary Glick Featured in Nature Reviews Drug Discovery

IFM Therapeutics' CEO Gary Glick recently spoke to Asher Mullard of Nature Reviews Drug Discovery about the promise and potential of #NLRP3 and #NLRP1 inflammasome inhibitors. 

Read the full article, "NLRP3 inhibitors stoke anti-inflammatory ambitions", on NRDD here

Media Contact

Andrew Bailey
Spectrum Science Communications
202-587-2521
abailey@spectrumscience.com